ACTG A5211

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 本AIDS临床试验组项目是一项II期、随机、双盲、多中心研究，比较3种剂量的SCH 417690与匹配安慰剂，分为3个阶段：（1）42天筛选期;（2）14天双盲、随机、安慰剂对照、添加治疗期，以评估SCH 417690的抗逆转录病毒活性;和（3）46周持续期，评估SCH 417690的长期安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This AIDS Clinical Trials Group project is a Phase II, randomized, double-blind, multicenter study of three doses of SCH 417690 vs. matching placebo with three phases: (1) 42-day screening phase; (2) 14-day double-blind, randomized, placebo-controlled, add-on phase to assess the antiretroviral activity of SCH 417690; and (3) 46-week continuation phase to assess the longer-term safety and tolerability of SCH 417690.